Peter Kufer Selected Research

Bites and Stings (Sting)

1/2021	Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
1/2021	The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
1/2020	Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events.
1/2020	The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
1/2018	Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
4/2016	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
6/2014	Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
1/2014	CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
12/2012	Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
6/2012	Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Kufer Research Topics

Disease

31	Neoplasms (Cancer) 01/2021 - 01/2002
24	Bites and Stings (Sting) 01/2021 - 04/2005
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2017 - 06/2011
6	Carcinoma (Carcinomatosis) 11/2010 - 07/2002
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 05/2005
5	Neoplasm Metastasis (Metastasis) 03/2017 - 08/2003
4	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2002
4	Melanoma (Melanoma, Malignant) 08/2010 - 05/2004
4	Lymphoma (Lymphomas) 06/2009 - 03/2007
3	Residual Neoplasm 01/2017 - 06/2011
3	Leukemia 06/2012 - 06/2009
2	Philadelphia Chromosome 04/2016 - 12/2012
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2014 - 01/2014
2	Breast Neoplasms (Breast Cancer) 11/2010 - 05/2005
2	Colorectal Neoplasms (Colorectal Cancer) 10/2010 - 07/2010
2	Lung Neoplasms (Lung Cancer) 05/2009 - 05/2004
2	Renal Cell Carcinoma (Grawitz Tumor) 02/2006 - 05/2005
1	Persistent Infection 01/2018
1	Human Influenza (Influenza) 01/2017
1	Pancreatitis 11/2010
1	Tics (Tic) 10/2010
1	Hematologic Neoplasms (Hematological Malignancy) 06/2009
1	Autoimmune Diseases (Autoimmune Disease) 03/2009
1	Rheumatoid Arthritis 03/2009
1	Celiac Disease (Celiac Sprue) 03/2009
1	Stomach Neoplasms (Stomach Cancer) 01/2009
1	Adenocarcinoma 01/2009
1	Lymphopenia (Lymphocytopenia) 05/2006

Drug/Important Bio-Agent (IBA)

14	blinatumomabIBA 01/2021 - 08/2008
14	Epithelial Cell Adhesion MoleculeIBA 01/2015 - 04/2005
11	AntigensIBA 01/2020 - 01/2002
10	AntibodiesIBA 12/2012 - 05/2005
7	CytokinesIBA 01/2018 - 02/2006
6	Single-Chain AntibodiesIBA 01/2018 - 04/2005
6	Proteins (Proteins, Gene)FDA Link 01/2017 - 12/2005
5	Monoclonal AntibodiesIBA 08/2010 - 05/2005
4	Surface Antigens (Surface Antigen)IBA 01/2020 - 02/2006
4	Bispecific AntibodiesIBA 08/2010 - 08/2003
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2012 - 04/2007
3	EpitopesIBA 11/2010 - 04/2007
3	Peptides (Polypeptides)IBA 06/2010 - 05/2005
2	PasotuxizumabIBA 01/2021 - 12/2012
2	AMG 330IBA 06/2014 - 01/2014
2	Pharmaceutical PreparationsIBA 12/2012 - 04/2007
2	Immunoglobulin G (IgG)IBA 11/2010 - 05/2005
2	EdrecolomabIBA 11/2010 - 07/2002
2	Complement System Proteins (Complement)IBA 11/2010 - 08/2010
2	VaccinesIBA 06/2010 - 01/2002
2	CD3 ComplexIBA 01/2008 - 04/2007
2	Interleukin-2 (IL2)IBA 09/2006 - 02/2006
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2006 - 02/2006
2	Keratins (Keratin)IBA 05/2005 - 01/2002
1	AndrogensIBA 01/2021
1	Human immunodeficiency virus 1 gp120 proteinIBA 01/2018
1	Antiviral Agents (Antivirals)IBA 01/2018
1	LectinsIBA 06/2014
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 06/2014
1	CD19 AntigensIBA 06/2011
1	adecatumumabIBA 11/2010
1	Cell Adhesion MoleculesIBA 10/2010
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 10/2010
1	AgarIBA 10/2010
1	Chondroitin Sulfate ProteoglycansIBA 08/2010
1	HMW-MAAIBA 08/2010
1	Cetuximab (Erbitux)FDA Link 07/2010
1	ErbB Receptors (EGF Receptor)IBA 07/2010
1	Threonine (L-Threonine)FDA Link 06/2010
1	AcetylgalactosamineIBA 06/2010
1	CarbohydratesIBA 06/2010
1	OligosaccharidesIBA 06/2010
1	Polysaccharides (Glycans)IBA 06/2010
1	GlycopeptidesIBA 06/2010
1	Serine (L-Serine)FDA Link 06/2010
1	Tn antigenIBA 06/2010
1	Carcinoembryonic AntigenIBA 05/2009
1	Phospholipases (Phospholipase)IBA 05/2009
1	Rituximab (Mabthera)FDA Link 03/2009
1	CTLA-4 AntigenIBA 02/2009
1	DNA (Deoxyribonucleic Acid)IBA 01/2009
1	EnzymesIBA 01/2009
1	CalciumIBA 01/2009
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2009
1	Propidium (Propidium Iodide)IBA 01/2009
1	Adenylate KinaseIBA 01/2009
1	CaspasesIBA 01/2009
1	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneIBA 01/2009
1	Dexamethasone (Maxidex)FDA LinkGeneric 10/2007
1	GlucocorticoidsIBA 10/2007
1	SYBR Green IIBA 06/2007
1	EphA2 ReceptorIBA 04/2007
1	Immunoglobulin FragmentsIBA 09/2006
1	Complementary DNA (cDNA)IBA 02/2006

Therapy/Procedure

17	Therapeutics 01/2021 - 05/2005
5	Drug Therapy (Chemotherapy) 12/2012 - 05/2005
5	Immunotherapy 11/2010 - 01/2002
2	Castration 01/2021 - 01/2021
2	Injections 07/2006 - 04/2005
1	Duration of Therapy 01/2018
1	Intraperitoneal Injections 12/2012
1	Treatment Delay 07/2006